OTCM
KBLB
Market cap100mUSD
Oct 08, Last price
0.09USD
1D
5.36%
1Q
-11.98%
Jan 2017
68.97%
IPO
80.80%
Name
Kraig Biocraft Laboratories Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Kraig Biocraft Laboratories, Inc. develops protein-based fibers using recombinant DNA technology for commercial applications in the textile and specialty fiber industries in the United States. Its primary proprietary fiber technology includes natural and engineered variants of spider silk produced in domesticated mulberry silkworms, as well as uses genetically engineered silkworms that produce spider silk proteins to create its recombinant spider silk. The company’s products are used in performance apparel, workwear, filtration, luxury fashion, flexible composites, medical implants, cosmetics, and other applications; military and police for its ballistic protection; and geotextiles, safe and protective clothing, textiles used in transportation and buildings, and functional and sportive textiles. Kraig Biocraft Laboratories, Inc. was incorporated in 2006 and is headquartered in Ann Arbor, Michigan.
Key people
Kim Thompson
President, Chief Executive Officer, Chief Financial Officer, Director · since 2006
Kenneth Le
Director of government relations, President of Prodigy Textiles · since 2019
Jonathan Rice
Chief Operating Officer · since 2015
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||